Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease
Abstract
:1. Introduction
2. Results
2.1. Ticagrelor, But Not Clopidogrel, Increases SIRT1 and HES1 mRNA Levels
2.2. Correlation Analyses Between SIRT1 and HES1 mRNA Levels and Markers of Endothelial Dysfunction in Treated Patients
3. Discussion
4. Material and Methods
4.1. Study Design and Population/Randomization and Interventions
4.2. Blood Samples
4.3. RNA Isolation and cDNA Synthesis
4.4. Droplet Digital PCR Reaction
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Cannon, C.P.; Harrington, R.A.; James, S.; Ardissino, D.; Becker, R.C.; Emanuelsson, H.; Husted, S.; Katus, H.; Keltai, M.; Khurmi, N.S.; et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet 2010, 375, 283–293. [Google Scholar] [CrossRef]
- Vieceli Dalla Sega, F.; Fortini, F.; Aquila, G.; Pavasini, R.; Biscaglia, S.; Bernucci, D.; Del Franco, A.; Tonet, E.; Rizzo, P.; Ferrari, R.; et al. Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF). Front. Physiol. 2018, 9, 337. [Google Scholar] [CrossRef] [PubMed]
- Fromonot, J.; Dignat-Georges, F.; Rossi, P.; Mottola, G.; Kipson, N.; Ruf, J.; Bonello, L.; Guieu, R.; Paganelli, F. Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level. J. Am. Coll Cardiol. 2016, 67, 1967–1968. [Google Scholar] [CrossRef] [PubMed]
- Cattaneo, M.; Schulz, R.; Nylander, S. Adenosine-mediated effects of ticagrelor: Evidence and potential clinical relevance. J. Am. Coll Cardiol. 2014, 63, 2503–2509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wallentin, L.; Becker, R.C.; Budaj, A.; Cannon, C.P.; Emanuelsson, H.; Held, C.; Horrow, J.; Husted, S.; James, S.; Katus, H.; et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009, 361, 1045–1057. [Google Scholar] [CrossRef]
- Campo, G.; Vieceli Dalla Sega, F.; Pavasini, R.; Aquila, G.; Gallo, F.; Fortini, F.; Tonet, E.; Cimaglia, P.; Del Franco, A.; Pestelli, G.; et al. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. Thromb Haemost 2017, 117, 1208–1216. [Google Scholar] [CrossRef] [Green Version]
- Mangiacapra, F.; Panaioli, E.; Colaiori, I.; Ricottini, E.; Lauria Pantano, A.; Pozzilli, P.; Barbato, E.; Di Sciascio, G. Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients). Circulation 2016, 134, 835–837. [Google Scholar] [CrossRef] [Green Version]
- Bonaca, M.P.; Bhatt, D.L.; Cohen, M.; Steg, P.G.; Storey, R.F.; Jensen, E.C.; Magnani, G.; Bansilal, S.; Fish, M.P.; Im, K.; et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 2015, 372, 1791–1800. [Google Scholar] [CrossRef] [Green Version]
- Bonello, L.; Laine, M.; Kipson, N.; Mancini, J.; Helal, O.; Fromonot, J.; Gariboldi, V.; Condo, J.; Thuny, F.; Frere, C.; et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J. Am. Coll Cardiol. 2014, 63, 872–877. [Google Scholar] [CrossRef]
- Li, X.; Wang, Q.; Xue, Y.; Chen, J.; Lv, Q. Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients. Basic Clin. Pharmacol. Toxicol. 2017, 120, 610–614. [Google Scholar] [CrossRef] [Green Version]
- Ramkumar, V.; Hallam, D.M.; Nie, Z. Adenosine, oxidative stress and cytoprotection. Jpn. J. Pharmacol. 2001, 86, 265–274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cekic, C.; Linden, J. Purinergic regulation of the immune system. Nat. Rev. Immunol. 2016, 16, 177–192. [Google Scholar] [CrossRef] [PubMed]
- Vieceli Dalla Sega, F.; Fortini, F.; Aquila, G.; Campo, G.; Vaccarezza, M.; Rizzo, P. Notch Signaling Regulates Immune Responses in Atherosclerosis. Front. Immunol. 2019, 10, 1130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, H.K.; Iwagaki, H.; Hamano, R.; Wake, H.; Kanke, T.; Liu, K.; Yoshino, T.; Tanaka, N.; Nishibori, M. Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated. Br. J. Pharmacol. 2007, 150, 816–822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, Y.; Jiang, W.; Liu, L.; Wang, X.; Ding, C.; Tian, Z.; Zhou, R. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 2015, 160, 62–73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sokolowska, M.; Chen, L.Y.; Liu, Y.; Martinez-Anton, A.; Qi, H.Y.; Logun, C.; Alsaaty, S.; Park, Y.H.; Kastner, D.L.; Chae, J.J.; et al. Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages. J. Immunol. 2015, 194, 5472–5487. [Google Scholar] [CrossRef] [Green Version]
- Zhou, W.; Chen, C.; Chen, Z.; Liu, L.; Jiang, J.; Wu, Z.; Zhao, M.; Chen, Y. NLRP3: A Novel Mediator in Cardiovascular Disease. J. Immunol. Res. 2018, 2018, 5702103. [Google Scholar] [CrossRef]
- Zou, X.L.; Chen, Z.G.; Zhang, T.T.; Feng, D.Y.; Li, H.T.; Yang, H.L. Th17/Treg homeostasis, but not Th1/Th2 homeostasis, is implicated in exacerbation of human bronchial asthma. Ther. Clin. Risk Manag. 2018, 14, 1627–1636. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Wan, H.; Tang, W.; Ni, Y.; Hou, X.; Pan, L.; Song, Y.; Shi, G. Critical roles of adenosine A2A receptor in regulating the balance of Treg/Th17 cells in allergic asthma. Clin. Respir. J. 2018, 12, 149–157. [Google Scholar] [CrossRef]
- Francois, V.; Shehade, H.; Acolty, V.; Preyat, N.; Delree, P.; Moser, M.; Oldenhove, G. Intestinal immunopathology is associated with decreased CD73-generated adenosine during lethal infection. Mucosal Immunol. 2015, 8, 773–784. [Google Scholar] [CrossRef] [Green Version]
- Zarek, P.E.; Huang, C.T.; Lutz, E.R.; Kowalski, J.; Horton, M.R.; Linden, J.; Drake, C.G.; Powell, J.D. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008, 111, 251–259. [Google Scholar] [CrossRef] [PubMed]
- Potekhina, A.V.; Pylaeva, E.; Provatorov, S.; Ruleva, N.; Masenko, V.; Noeva, E.; Krasnikova, T.; Arefieva, T. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015, 238, 17–21. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X.; Yu, X.; Ding, Y.J.; Fu, Q.Q.; Xie, J.J.; Tang, T.T.; Yao, R.; Chen, Y.; Liao, Y.H. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 2008, 127, 89–97. [Google Scholar] [CrossRef] [PubMed]
- Li, X.N.; Pan, X.; Qiu, D. Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage. Int. J. Clin. Exp. Med. 2014, 7, 5324–5329. [Google Scholar] [PubMed]
- Wang, H.; Ying, H.; Wang, S.; Gu, X.; Weng, Y.; Peng, W.; Xia, D.; Yu, W. Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease. Clin. Respir. J. 2015, 9, 330–341. [Google Scholar] [CrossRef] [PubMed]
- Sorrentino, C.; Hossain, F.; Rodriguez, P.C.; Sierra, R.A.; Pannuti, A.; Osborne, B.A.; Minter, L.M.; Miele, L.; Morello, S. Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8+T-Cells. Front. Immunol. 2019, 10, 162. [Google Scholar] [CrossRef]
- Bergstrom, I.; Backteman, K.; Lundberg, A.; Ernerudh, J.; Jonasson, L. Persistent accumulation of interferon-gamma-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. Atherosclerosis 2012, 224, 515–520. [Google Scholar] [CrossRef] [Green Version]
- Kemeny, D.M.; Vyas, B.; Vukmanovic-Stejic, M.; Thomas, M.J.; Noble, A.; Loh, L.C.; O’Connor, B.J. CD8(+) T cell subsets and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999, 160, S33–S37. [Google Scholar] [CrossRef]
- Ferrari, R.; Rizzo, P. The Notch pathway: A novel target for myocardial remodelling therapy? Eur. Heart J. 2014, 35, 2140–2145. [Google Scholar] [CrossRef] [Green Version]
- Zhao, L.L.; Wang, C.; Hu, S.N.; Li, L.L.; Wang, Y.; Hou, J.B.; Yu, B.; Zhu, Y.C.; Jia, H.B.; Zhe, C.Y.; et al. P1788The relationship between the jagged1 levels of human blood mononuclear cell surface and plaque vulnerability. Eur. Heart J. 2017, 38. [Google Scholar] [CrossRef] [Green Version]
- Aquila, G.; Fortini, C.; Pannuti, A.; Delbue, S.; Pannella, M.; Morelli, M.B.; Caliceti, C.; Castriota, F.; de Mattei, M.; Ongaro, A.; et al. Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: A pilot study. J. Transl. Med. 2017, 15, 98. [Google Scholar] [CrossRef] [PubMed]
- Tilley, A.E.; Harvey, B.G.; Heguy, A.; Hackett, N.R.; Wang, R.; O’Connor, T.P.; Crystal, R.G. Down-regulation of the notch pathway in human airway epithelium in association with smoking and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009, 179, 457–466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zong, D.; Li, J.; Cai, S.; He, S.; Liu, Q.; Jiang, J.; Chen, S.; Long, Y.; Chen, Y.; Chen, P.; et al. Notch1 regulates endothelial apoptosis via the ERK pathway in chronic obstructive pulmonary disease. Am. J. Physiol. Cell Physiol. 2018, 315, C330–C340. [Google Scholar] [CrossRef] [PubMed]
- Fortini, F.; Vieceli Dalla Sega, F.; Caliceti, C.; Lambertini, E.; Pannuti, A.; Peiffer, D.S.; Balla, C.; Rizzo, P. Estrogen-mediated protection against coronary heart disease: The role of the Notch pathway. J. Steroid. Biochem. Mol. Biol. 2019, 189, 87–100. [Google Scholar] [CrossRef] [PubMed]
- Vieceli Dalla Sega, F.; Aquila, G.; Fortini, F.; Vaccarezza, M.; Secchiero, P.; Rizzo, P.; Campo, G. Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. Biofactors 2017, 43, 475–485. [Google Scholar] [CrossRef]
- Salminen, A.; Kaarniranta, K.; Kauppinen, A. Crosstalk between Oxidative Stress and SIRT1: Impact on the Aging Process. Int. J. Mol. Sci. 2013, 14, 3834–3859. [Google Scholar] [CrossRef] [Green Version]
- Vachharajani, V.T.; Liu, T.; Wang, X.; Hoth, J.J.; Yoza, B.K.; McCall, C.E. Sirtuins Link Inflammation and Metabolism. J. Immunol. Res. 2016, 2016, 8167273. [Google Scholar] [CrossRef] [Green Version]
- Breitenstein, A.; Wyss, C.A.; Spescha, R.D.; Franzeck, F.C.; Hof, D.; Riwanto, M.; Hasun, M.; Akhmedov, A.; von Eckardstein, A.; Maier, W.; et al. Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS ONE 2013, 8, e53106. [Google Scholar] [CrossRef] [Green Version]
- Conti, V.; Corbi, G.; Manzo, V.; Malangone, P.; Vitale, C.; Maglio, A.; Cotugno, R.; Capaccio, D.; Marino, L.; Selleri, C.; et al. SIRT1 Activity in Peripheral Blood Mononuclear Cells Correlates with Altered Lung Function in Patients with Chronic Obstructive Pulmonary Disease. Oxidative Med. Cell. Longev. 2018, 2018, 8. [Google Scholar] [CrossRef]
- Bonello, L.; Frere, C.; Cointe, S.; Laine, M.; Mancini, J.; Thuny, F.; Kerbaul, F.; Lemesle, G.; Paganelli, F.; Guieu, R.; et al. Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. Int. J. Cardiol. 2015, 187, 502–507. [Google Scholar] [CrossRef]
- Torngren, K.; Ohman, J.; Salmi, H.; Larsson, J.; Erlinge, D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013, 124, 252–258. [Google Scholar] [CrossRef] [PubMed]
- Alexopoulos, D.; Moulias, A.; Koutsogiannis, N.; Xanthopoulou, I.; Kakkavas, A.; Mavronasiou, E.; Davlouros, P.; Hahalis, G. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: An exploratory study. Circ. Cardiovasc. Interv. 2013, 6, 277–283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Storey, R.F.; James, S.K.; Siegbahn, A.; Varenhorst, C.; Held, C.; Ycas, J.; Husted, S.E.; Cannon, C.P.; Becker, R.C.; Steg, P.G.; et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014, 25, 517–525. [Google Scholar] [CrossRef]
- Armstrong, D.; Summers, C.; Ewart, L.; Nylander, S.; Sidaway, J.E.; van Giezen, J.J. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J. Cardiovasc. Pharm. Ther. 2014, 19, 209–219. [Google Scholar] [CrossRef] [PubMed]
- Van Giezen, J.J.; Sidaway, J.; Glaves, P.; Kirk, I.; Bjorkman, J.A. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J. Cardiovasc. Pharm. Ther. 2012, 17, 164–172. [Google Scholar] [CrossRef] [PubMed]
- Wittfeldt, A.; Emanuelsson, H.; Brandrup-Wognsen, G.; van Giezen, J.J.; Jonasson, J.; Nylander, S.; Gan, L.M. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J. Am. Coll Cardiol. 2013, 61, 723–727. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aungraheeta, R.; Conibear, A.; Butler, M.; Kelly, E.; Nylander, S.; Mumford, A.; Mundell, S.J. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood 2016, 128, 2717–2728. [Google Scholar] [CrossRef]
- Thomas, M.; Judge, H.; Dockrell, D.; Sabroe, I.; Storey, R. 215 Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia. Heart 2014, 100, A117–A118. [Google Scholar] [CrossRef]
- Nylander, S.; Schulz, R. Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines. Br. J. Pharmacol. 2016, 173, 1163–1178. [Google Scholar] [CrossRef] [Green Version]
- Husted, S.; Storey, R.F.; Harrington, R.A.; Emanuelsson, H.; Cannon, C.P. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin. Cardiol. 2010, 33, 206–212. [Google Scholar] [CrossRef]
- Ariotti, S.; Ortega-Paz, L.; van Leeuwen, M.; Brugaletta, S.; Leonardi, S.; Akkerhuis, K.M.; Rimoldi, S.F.; Janssens, G.; Gianni, U.; van den Berge, J.C.; et al. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. JACC Cardiovasc. Interv. 2018, 11, 1576–1586. [Google Scholar] [CrossRef] [PubMed]
- Teng, R.; Butler, K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J. Drug Assess. 2013, 2, 30–39. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agnoletti, L.; Curello, S.; Bachetti, T.; Malacarne, F.; Gaia, G.; Comini, L.; Volterrani, M.; Bonetti, P.; Parrinello, G.; Cadei, M.; et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: Role of tumor necrosis factor-alpha. Circulation 1999, 100, 1983–1991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Valgimigli, M.; Agnoletti, L.; Curello, S.; Comini, L.; Francolini, G.; Mastrorilli, F.; Merli, E.; Pirani, R.; Guardigli, G.; Grigolato, P.G.; et al. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: A possible link to pan-coronary syndromes. Circulation 2003, 107, 264–270. [Google Scholar] [CrossRef] [PubMed]
- Cimaglia, P.; Vieceli Dalla Sega, F.; Vitali, F.; Lodolini, V.; Bernucci, D.; Passarini, G.; Fortini, F.; Marracino, L.; Aquila, G.; Rizzo, P.; et al. Effectiveness of a Novel Nutraceutical Compound Containing Red Yeast Rice, Polymethoxyflavones and Antioxidants in the Modulation of Cholesterol Levels in Subjects With Hypercholesterolemia and Low-Moderate Cardiovascular Risk: The NIRVANA Study. Front. Physiol. 2019, 10, 217. [Google Scholar] [CrossRef] [PubMed]
- Moscarelli, M.; Devito, F.; Fattouch, K.; Lancellotti, P.; Ciccone, M.M.; Rizzo, P.; Gaudino, M.; Marchese, A.; Angelini, G.; Speziale, G. The effect of surgical versus transcatheter aortic valve replacement on endothelial function. An observational study. Int. J. Surg. 2019, 63, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fabbri, L.M.; Rabe, K.F. From COPD to chronic systemic inflammatory syndrome? Lancet 2007, 370, 797–799. [Google Scholar] [CrossRef]
- Szucs, B.; Szucs, C.; Petrekanits, M.; Varga, J.T. Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article. Int J. Mol. Sci 2019, 20, 4329. [Google Scholar] [CrossRef] [Green Version]
- Imam, H.; Nguyen, T.H.; De Caterina, R.; Nooney, V.B.; Chong, C.R.; Horowitz, J.D.; Chirkov, Y.Y. Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y12 receptor antagonists. Thromb. Res. 2019, 181, 92–98. [Google Scholar] [CrossRef]
- Zheng, W.; Li, Y.; Tian, J.; Li, L.; Xie, L.; Mao, Q.; Tong, W.; Zhou, D.; Azzalini, L.; Zhao, X. Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. Biomed. Res. Int. 2019, 2019, 3170957. [Google Scholar] [CrossRef] [Green Version]
- Jeong, H.S.; Hong, S.J.; Cho, S.-A.; Kim, J.-H.; Cho, J.Y.; Lee, S.H.; Joo, H.J.; Park, J.H.; Yu, C.W.; Lim, D.-S. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. JACC: Cardiovasc. Interv. 2017, 10, 1646–1658. [Google Scholar]
- Van den Berg, T.N.; El Messaoudi, S.; Rongen, G.A.; van den Broek, P.H.; Bilos, A.; Donders, A.R.; Gomes, M.E.; Riksen, N.P. Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. PLoS ONE 2015, 10, e0137560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGuinness, D.; McGuinness, D.H.; McCaul, J.A.; Shiels, P.G. Sirtuins, bioageing, and cancer. J. Aging Res. 2011, 2011, 235754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beier, U.H.; Wang, L.; Bhatti, T.R.; Liu, Y.; Han, R.; Ge, G.; Hancock, W.W. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol. Cell Biol. 2011, 31, 1022–1029. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, R.; Chen, H.Z.; Liu, J.J.; Jia, Y.Y.; Zhang, Z.Q.; Yang, R.F.; Zhang, Y.; Xu, J.; Wei, Y.S.; Liu, D.P.; et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem. 2010, 285, 7097–7110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stein, S.; Schafer, N.; Breitenstein, A.; Besler, C.; Winnik, S.; Lohmann, C.; Heinrich, K.; Brokopp, C.E.; Handschin, C.; Landmesser, U.; et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/- mice. Aging (Albany NY) 2010, 2, 353–360. [Google Scholar] [CrossRef] [Green Version]
- Guarani, V.; Deflorian, G.; Franco, C.A.; Krüger, M.; Phng, L.K.; Bentley, K.; Toussaint, L.; Dequiedt, F.; Mostoslavsky, R.; Schmidt, M.H.H.; et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473, 234–238. [Google Scholar] [CrossRef]
- Bai, X.; He, T.; Liu, Y.; Zhang, J.; Li, X.; Shi, J.; Wang, K.; Han, F.; Zhang, W.; Zhang, Y.; et al. Acetylation-Dependent Regulation of Notch Signaling in Macrophages by SIRT1 Affects Sepsis Development. Front. Immunol. 2018, 9, 762. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Yang, X.; He, Y.; Wang, W.; Zhang, J.; Zhang, W.; Jing, T.; Wang, B.; Lin, R. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology 2017, 222, 552–561. [Google Scholar] [CrossRef]
- Lee, S.J.; Baek, S.E.; Jang, M.A.; Kim, C.D. SIRT1 inhibits monocyte adhesion to the vascular endothelium by suppressing Mac-1 expression on monocytes. Exp. Mol. Med. 2019, 51, 47. [Google Scholar] [CrossRef] [Green Version]
- Yao, H.; Sundar, I.K.; Ahmad, T.; Lerner, C.; Gerloff, J.; Friedman, A.E.; Phipps, R.P.; Sime, P.J.; McBurney, M.W.; Guarente, L.; et al. SIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism. Am. J. Physiol. Lung Cell Mol. Physiol. 2014, 306, L816–L828. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanigaki, K.; Honjo, T. Regulation of lymphocyte development by Notch signaling. Nat. Immunol. 2007, 8, 451–456. [Google Scholar] [CrossRef] [PubMed]
- Shang, Y.; Smith, S.; Hu, X. Role of Notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell 2016, 7, 159–174. [Google Scholar] [CrossRef] [Green Version]
- Shang, Y.; Coppo, M.; He, T.; Ning, F.; Yu, L.; Kang, L.; Zhang, B.; Ju, C.; Qiao, Y.; Zhao, B.; et al. The transcriptional repressor Hes1 attenuates inflammation by regulating transcription elongation. Nature Immunol. 2016, 17, 930. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, X.; Li, X.; Ning, F.; Shang, Y.; Hu, X. TLE4 acts as a corepressor of Hes1 to inhibit inflammatory responses in macrophages. Protein Cell 2019, 10, 300–305. [Google Scholar] [CrossRef] [Green Version]
- Hu, X.; Chung, A.Y.; Wu, I.; Foldi, J.; Chen, J.; Ji, J.D.; Tateya, T.; Kang, Y.J.; Han, J.; Gessler, M.; et al. Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways. Immunity 2008, 29, 691–703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Espinoza, I.; Miele, L. Notch inhibitors for cancer treatment. Pharmacol. Ther. 2013, 139, 95–110. [Google Scholar] [CrossRef] [Green Version]
- Rizzo, P.; Miele, L.; Ferrari, R. The Notch pathway: A crossroad between the life and death of the endothelium. Eur. Heart J. 2013, 34, 2504–2509. [Google Scholar] [CrossRef] [Green Version]
- Aquila, G.; Kostina, A.; Vieceli Dalla Sega, F.; Shlyakhto, E.; Kostareva, A.; Marracino, L.; Ferrari, R.; Rizzo, P.; Malaschicheva, A. The Notch pathway: A novel therapeutic target for cardiovascular diseases? Expert Opin. Ther. Targets 2019, 1–16. [Google Scholar] [CrossRef]
- Aquila, G.; Pannella, M.; Morelli, M.B.; Caliceti, C.; Fortini, C.; Rizzo, P.; Ferrari, R. The role of Notch pathway in cardiovascular diseases. Glob. Cardiol. Sci. Pract. 2013, 2013, 364–371. [Google Scholar] [CrossRef]
- Rizzo, P.; Ferrari, R. The Notch pathway: A new therapeutic target in atherosclerosis? Eur. Heart J. Suppl. 2015, 17, A74–A76. [Google Scholar] [CrossRef] [Green Version]
- Liu, X.; Qu, J.; Xue, W.; He, L.; Wang, J.; Xi, X.; Liu, X.; Yin, Y.; Qu, Y. Bioinformatics-based identification of potential microRNA biomarkers in frequent and non-frequent exacerbators of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 13, 1217–1228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takata, T.; Ishikawa, F. Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression. Biochem. Biophys. Res. Commun. 2003, 301, 250–257. [Google Scholar] [CrossRef]
- Fusco, S.; Leone, L.; Barbati, S.A.; Samengo, D.; Piacentini, R.; Maulucci, G.; Toietta, G.; Spinelli, M.; McBurney, M.; Pani, G.; et al. A CREB-Sirt1-Hes1 Circuitry Mediates Neural Stem Cell Response to Glucose Availability. Cell Rep. 2016, 14, 1195–1205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hisahara, S.; Chiba, S.; Matsumoto, H.; Tanno, M.; Yagi, H.; Shimohama, S.; Sato, M.; Horio, Y. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc. Natl. Acad. Sci. USA 2008, 105, 15599–15604. [Google Scholar] [CrossRef] [Green Version]
- Anagnostis, A.; Neofytou, E.; Soulitzis, N.; Avgousti, M.; Stroumpos, C.; Drositis, I.; Siafakas, N.; Tzortzaki, E. Epidermal growth factor (EGF) and its receptors (ERBBs) in smokers with and without COPD: An index of epithelial repair imbalance? Eur. Respir. J. 2012, 40, P4585. [Google Scholar]
- Vallath, S.; Hynds, R.E.; Succony, L.; Janes, S.M.; Giangreco, A. Targeting EGFR signalling in chronic lung disease: Therapeutic challenges and opportunities. Eur. Respir. J. 2014, 44, 513–522. [Google Scholar] [CrossRef] [Green Version]
- Makki, N.; Thiel, K.W.; Miller Jr, F.J. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int. J. Mol. Sci. 2013, 14, 20597–20613. [Google Scholar] [CrossRef] [Green Version]
- Pancewicz-Wojtkiewicz, J. Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer Med. 2016, 5, 3572–3578. [Google Scholar] [CrossRef]
- Kolev, V.; Mandinova, A.; Guinea-Viniegra, J.; Hu, B.; Lefort, K.; Lambertini, C.; Neel, V.; Dummer, R.; Wagner, E.F.; Dotto, G.P. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 2008, 10, 902–911. [Google Scholar] [CrossRef] [Green Version]
- Byles, V.; Zhu, L.; Lovaas, J.D.; Chmilewski, L.K.; Wang, J.; Faller, D.V.; Dai, Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012, 31, 4619–4629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schreiner, C.E.; Kumerz, M.; Gesslbauer, J.; Schachner, D.; Joa, H.; Erker, T.; Atanasov, A.G.; Heiss, E.H.; Dirsch, V.M. Resveratrol blocks Akt activation in angiotensin II- or EGF-stimulated vascular smooth muscle cells in a redox-independent manner. Cardiovasc Res. 2011, 90, 140–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- From the Global Strategy for the Diagnosis, M.a.P.o.C. Global Initiative for Chronic Obstructive Lung Disease (GOLD), updated 2014. Available online: https://goldcopd.org/ (accessed on 24 March 2014).
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aquila, G.; Vieceli Dalla Sega, F.; Marracino, L.; Pavasini, R.; Cardelli, L.S.; Piredda, A.; Scoccia, A.; Martino, V.; Fortini, F.; Bononi, I.; et al. Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. Int. J. Mol. Sci. 2020, 21, 1576. https://doi.org/10.3390/ijms21051576
Aquila G, Vieceli Dalla Sega F, Marracino L, Pavasini R, Cardelli LS, Piredda A, Scoccia A, Martino V, Fortini F, Bononi I, et al. Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. International Journal of Molecular Sciences. 2020; 21(5):1576. https://doi.org/10.3390/ijms21051576
Chicago/Turabian StyleAquila, Giorgio, Francesco Vieceli Dalla Sega, Luisa Marracino, Rita Pavasini, Laura Sofia Cardelli, Anna Piredda, Alessandra Scoccia, Valeria Martino, Francesca Fortini, Ilaria Bononi, and et al. 2020. "Ticagrelor Increases SIRT1 and HES1 mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease" International Journal of Molecular Sciences 21, no. 5: 1576. https://doi.org/10.3390/ijms21051576